This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eskelin, S Articles by Kivelä, T Search for Related Content PubMed PubMed Citation Articles by Eskelin, S Articles by Kivelä, T

Mode of presentation and time to treatment of uveal melanoma in Finland

Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, Finland

Correspondence to:
Correspondence to:
Sebastian Eskelin, MD, Ocular Oncology Service, Department of Ophthalmology, Helsinki University Central Hospital, Haartmaninkatu 4C, PL 220, FIN-00029 HUS, Helsinki, Finland;
sebastian.eskelin{at}hus.fi

Aims: To investigate the current referral pattern and delays in treatment of patients with primary uveal melanoma.

Methods: 184 consecutive Finnish patients with uveal melanoma diagnosed between July 1994 and June 1999 were eligible, and 159 were enrolled (inclusion rate, 86%). Their mean age was 60 years (range 14–87). The dates of visits to dispensing optician, physician, ophthalmologist and ocular oncologist, the presence of symptoms, and reason for consultation were determined by structured telephone interview. Time intervals to treatment planning and treatment were calculated.

Results: 139 patients (87%) had symptoms at presentation and 44 patients (28%) had been seen by an ophthalmologist less than 2 years previously. The median height of the tumour was 6 mm (range, 1.0–17.0) and its largest basal diameter 11 mm (range 2.5–22.0) at diagnosis. Melanoma developed from a previously detected presumed naevus in 13 patients (8%). When the first contact was a dispensing optician (15%) the median time to treatment planning was 22 days (range 1–1156). When a physician other than an ophthalmologist (19%) was contacted the delay was 68 days (range 0–1283) and when an ophthalmologist (65%) was seen it was 34 days (range 1–1426). These differences were not significant (p=0.32). The chance of being referred at first visit was 89%. Median time to treatment was not associated with symptoms (p=0.16) and tumour volume (p=0.29), but it was significantly different between patients who were and were not referred at first visit (140 days v 34 days; p<0.001) and between those treated by ruthenium and iodine brachytherapy (59 days v 33 days; p=0.009).

Conclusions: Analysis of delays in management indicates that earlier treatment could be achieved if dilated fundus examinations were performed without exceptions, all suspicious naevi were referred for a second opinion, and if the patients with melanoma were referred to the ocular oncology service concurrently with staging examinations done at the regional hospital.

Keywords: uveal melanoma; choroidal naevus

This article has been cited by other articles:

				V. Barak, S. Frenkel, K. Valyi-Nagy, L. Leach, M. A. Apushkin, A. Y. Lin, I. Kalickman, N. A. Baumann, J. Pe'er, A. J. Maniotis, et al. Using the Direct-Injection Model of Early Uveal Melanoma Hepatic Metastasis to Identify TPS as a Potentially Useful Serum Biomarker Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4399 - 4402. [Abstract] [Full Text] [PDF]

				L. Bergman, S. Seregard, B. Nilsson, G. Lundell, U. Ringborg, and B. Ragnarsson-Olding Uveal Melanoma Survival in Sweden from 1960 to 1998 Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3282 - 3287. [Abstract] [Full Text] [PDF]

				J Biswas, M Agarwal, S Krishnakumar, and M P Shanmugam Uveal melanoma: Finland v India Br. J. Ophthalmol., October 1, 2002; 86(10): 1193 - 1193. [Full Text]